TrialCancer prevention research (Philadelphia, Pa.)2015

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Daniel L Gillen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.